Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Exosomes derived from menstrual blood-derived mesenchymal stem cells and treadmill training restore motor function following SCI by activating PI3K/Akt pathway

Wang QH., Shi YH., Zhang LY., Jiang WW., Pu YX., Chen SY.

Animal Study on Spinal Cord Injury, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41316483
PMCID
PMC12664214
DOI
10.1186/s13287-025-04794-5
Citations
1

Abstract (original English)

Background Spinal cord injury (SCI) remains a global challenge due to limited neural regeneration and functional recovery. Emerging therapies, such as mesenchymal stem cell-derived exosomes and exercise training, have shown promise, but their individual efficacy is insufficient. The synergistic effects of menstrual blood-derived mesenchymal stem cell-derived exosomes (MenSCs-Exo) and weight-supported treadmill training (WSTT) in SCI repair remain unclear. This study investigated their combined therapeutic potential and underlying mechanisms in SCI rats. Methods A T10 spinal cord hemisection model was conducted in adult male Sprague-Dawley rats, which were randomized into five groups: Sham, SCI, Exo (200 µg MenSCs-Exo via tail vein injection every 48 h for 4 doses), TT (WSTT starting on day 3 post-SCI), and Exo + TT. Motor function was evaluated using the Basso, Beattie, and Bresnahan (BBB) scale and CatWalk XT ® gait analysis. Histological assessments included hematoxylin and eosin (H&E) staining, Masson's trichrome staining, immunofluorescence for β-tubulin III (Tuj1) and myelin basic protein (MBP), and transmission electron microscopy (TEM). Western blot analyzed fibrosis-related proteins (COL1, COL3, α-SMA) and PI3K/AKT pathway activation (p-AKT, PI3K, β-catenin, LEF1). Results Combined Exo + TT significantly improved motor function compared to monotherapies. BBB scores in t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansRatsRats, Sprague-DawleySpinal Cord InjuriesMesenchymal Stem Cell TransplantationPhysical Conditioning, AnimalRecovery of FunctionSignal Transduction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research